CJC1295 With DAC
[CAS 446262-90-4]

Identification

• Classification: Biochemical >> Peptide
• Name: CJC1295 With DAC
• Synonyms: 4-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[6-amino-1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[[6-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[(1-amino-5-carbamimidamido-1-oxopentan-2-yl)amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoylamino]-4-oxobutanoic acid
• Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆
• Molecular Weight: 3647.19
• CAS Registry Number: 446262-90-4
• SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN4C(=O)C=CC4=O)C(=O)N

chemBlink Chemical Story

CJC-1295 with DAC is a modified analogue of growth hormone-releasing hormone. The three letters distinguish it from the related peptide without the drug affinity complex. In this case the modification includes a chemical group designed to bind covalently to circulating albumin. The peptide is a defined substance before that association takes place; it is not a preparation of albumin itself or a form of growth hormone.

Binding to a circulating protein changes the context in which a peptide moves through the body. A small, unbound peptide can be exposed to clearance and degradation on a different time scale from a peptide associated with a larger carrier. The design question was whether coupling the two could sustain the signal longer. This is an example of altering the disposition of a molecule, not merely trying to make its receptor interaction stronger.

Teichman and colleagues studied the long-acting analogue in healthy adults and reported prolonged changes in growth hormone and insulin-like growth factor I. The two hormones are separate measurements. Growth hormone release is the nearer response to a releasing-hormone signal, whereas the change in insulin-like growth factor I is further downstream. A longer hormonal response does not establish therapeutic benefit, long-term safety, or improvement in physical performance. Those require specific studies with meaningful clinical or functional outcomes.

Identity is particularly important because similar names can refer to materially different preparations. FDA advisory materials distinguish the DAC free base corresponding to this CAS from related forms and salts. The label CJC-1295 alone is not a sufficient substitute for a characterized structure and formulation. Evidence from the long-acting compound should not be applied to a version lacking the affinity group. The central scientific lesson is that modification of a peptide's association with a carrier can change the timing of a measurable response, without proving that prolonging the response is beneficial.

References:
1. FDA. CJC-1295-related bulk drug substances advisory materials (2024). https://www.fda.gov/media/183819/download
2. FDA GSRS. CJC-1295, CAS 446262-90-4. https://precision.fda.gov/uniisearch/srs/unii/62RC32V9N7
3. Teichman SL et al. Study of long-acting CJC-1295 in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/

Read more stories